Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase

Christopher M Warren; Ruud L van den Brink; Sander Nieuwenhuis; Jos A Bosch

doi:10.1016/j.psyneuen.2017.01.029

Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase

Standard

Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase. / Warren, Christopher M; van den Brink, Ruud L; Nieuwenhuis, Sander; Bosch, Jos A.

in: PSYCHONEUROENDOCRINO, Jahrgang 78, 04.2017, S. 233-236.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Warren, CM, van den Brink, RL, Nieuwenhuis, S & Bosch, JA 2017, 'Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase', PSYCHONEUROENDOCRINO, Jg. 78, S. 233-236. https://doi.org/10.1016/j.psyneuen.2017.01.029

APA

Warren, C. M., van den Brink, R. L., Nieuwenhuis, S., & Bosch, J. A. (2017). Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase. PSYCHONEUROENDOCRINO, 78, 233-236. https://doi.org/10.1016/j.psyneuen.2017.01.029

Vancouver

Warren CM, van den Brink RL, Nieuwenhuis S, Bosch JA. Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase. PSYCHONEUROENDOCRINO. 2017 Apr;78:233-236. https://doi.org/10.1016/j.psyneuen.2017.01.029

Bibtex

@article{0d941ff1f0c245159d7693a3b55d37d0,

title = "Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase",

abstract = "It has been suggested that central norepinephrine (NE) activity may be inferred from increases in salivary alpha-amylase (SAA), but data in favor of this proposition are limited. We administered 40mg of atomoxetine, a selective NE transporter blocker that increases central NE levels, to 24 healthy adult participants in a double-blind, placebo-controlled cross-over design. Atomoxetine administration significantly increased SAA secretion and concentrations at 75-180min after treatment (more than doubling baseline levels). Consistent with evidence that elevation in central NE is a co-determinant of hypothalamic-pituitary-adrenal axis activity, salivary cortisol also approximately doubled at the same time points. Moreover, changes in salivary cortisol positively correlated with SAA (0.44",

keywords = "Adrenergic Uptake Inhibitors, Adult, Atomoxetine Hydrochloride, Cross-Over Studies, Double-Blind Method, Female, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Pituitary-Adrenal System, Saliva, Salivary alpha-Amylases, Young Adult, Journal Article, Randomized Controlled Trial",

author = "Warren, {Christopher M} and {van den Brink}, {Ruud L} and Sander Nieuwenhuis and Bosch, {Jos A}",

year = "2017",

month = apr,

doi = "10.1016/j.psyneuen.2017.01.029",

language = "English",

volume = "78",

pages = "233--236",

journal = "PSYCHONEUROENDOCRINO",

issn = "0306-4530",

publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Norepinephrine transporter blocker atomoxetine increases salivary alpha amylase

AU - Warren, Christopher M

AU - van den Brink, Ruud L

AU - Nieuwenhuis, Sander

AU - Bosch, Jos A

PY - 2017/4

Y1 - 2017/4

N2 - It has been suggested that central norepinephrine (NE) activity may be inferred from increases in salivary alpha-amylase (SAA), but data in favor of this proposition are limited. We administered 40mg of atomoxetine, a selective NE transporter blocker that increases central NE levels, to 24 healthy adult participants in a double-blind, placebo-controlled cross-over design. Atomoxetine administration significantly increased SAA secretion and concentrations at 75-180min after treatment (more than doubling baseline levels). Consistent with evidence that elevation in central NE is a co-determinant of hypothalamic-pituitary-adrenal axis activity, salivary cortisol also approximately doubled at the same time points. Moreover, changes in salivary cortisol positively correlated with SAA (0.44

AB - It has been suggested that central norepinephrine (NE) activity may be inferred from increases in salivary alpha-amylase (SAA), but data in favor of this proposition are limited. We administered 40mg of atomoxetine, a selective NE transporter blocker that increases central NE levels, to 24 healthy adult participants in a double-blind, placebo-controlled cross-over design. Atomoxetine administration significantly increased SAA secretion and concentrations at 75-180min after treatment (more than doubling baseline levels). Consistent with evidence that elevation in central NE is a co-determinant of hypothalamic-pituitary-adrenal axis activity, salivary cortisol also approximately doubled at the same time points. Moreover, changes in salivary cortisol positively correlated with SAA (0.44

KW - Adrenergic Uptake Inhibitors

KW - Adult

KW - Atomoxetine Hydrochloride

KW - Cross-Over Studies

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Hydrocortisone

KW - Hypothalamo-Hypophyseal System

KW - Male

KW - Pituitary-Adrenal System

KW - Saliva

KW - Salivary alpha-Amylases

KW - Young Adult

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1016/j.psyneuen.2017.01.029

DO - 10.1016/j.psyneuen.2017.01.029

M3 - SCORING: Journal article

C2 - 28232237

VL - 78

SP - 233

EP - 236

JO - PSYCHONEUROENDOCRINO

JF - PSYCHONEUROENDOCRINO

SN - 0306-4530

ER -